Calcitonin Gene-Related Peptide (CGRP) is a 37-amino acid Neuropeptide produced by alternative splicing of the calcitonin gene, functioning as one of the most potent vasodilators known and a critical mediator in Neurogenic inflammation, pain transmission, and Migraine pathophysiology. Released primarily from peripheral C-fibres and trigeminal sensory neurons, CGRP acts on heterodimeric receptors to trigger vasodilation, plasma extravasation, and immune cell activation, creating a self-amplifying cascade that underlies both protective responses to tissue damage and pathological pain states.
Think of CGRP as an emergency broadcast system built into your sensory nerves. When tissue damage occurs, peripheral nerve endings don't just send pain signals to the brain—they simultaneously release CGRP into the surrounding tissue like a sprinkler system spraying chemical messages. These messages tell local blood vessels to dilate immediately (like opening fire hydrants to full capacity), making vessel walls leaky so immune cells and plasma proteins can flood the injury site. It's a brilliant emergency response—the same nerves that detect the problem also coordinate the local repair team before the brain even registers pain.
But here's where the system can betray you: in Migraine, this sprinkler system activates around the brain's blood vessels without any actual tissue damage. The trigeminal nerve releases massive amounts of CGRP, causing cranial blood vessels to dilate and their walls to become leaky, creating the throbbing pain and inflammation. Worse, the CGRP itself sensitizes the nerve endings that released it, creating a vicious cycle—the alarm system is now triggered by its own alarm. This is why blocking CGRP (with monoclonal antibodies or gepants) can break the cycle: you're essentially installing a filter on the sprinkler system so it only activates for real emergencies, not false alarms.
CGRP is produced through alternative splicing of the CALC1 gene, which normally encodes calcitonin in thyroid C-cells but produces CGRP in neurons. The 37-amino acid peptide is synthesized in dorsal root ganglia and trigeminal ganglia, packaged into dense-core vesicles, and transported to peripheral nerve terminals.
Release Cascade:
Noxious stimuli (mechanical, thermal, chemical) → activation of TRPV1, TRPA1, or other TRP channels on C-fibres → calcium influx → exocytosis of CGRP-containing vesicles → CGRP release into local tissue and vasculature
Receptor Activation:
CGRP binds to a heterodimeric receptor complex composed of:
- CALCRL (calcitonin receptor-like receptor) — the ligand-binding component
- RAMP1 (receptor activity-modifying protein 1) — determines CGRP specificity
- RCP (receptor component protein) — necessary for intracellular signaling
CGRP + CALCRL-RAMP1 complex → Gs protein activation → adenylyl cyclase activation → cAMP production → PKA activation → multiple downstream effects:
-
Vascular effects: PKA → phosphorylation of myosin light chain kinase → smooth muscle relaxation → vasodilation (10-100x more potent than Substance P)
-
Endothelial permeability: PKA → phosphorylation of VE-cadherin and ZO-1 → Tight junctions disruption → plasma extravasation
-
Immune activation: CGRP → Mast Cell Degranulation → histamine, TNF-α, and prostaglandin release → amplification of inflammatory response
-
Sensitization: CGRP → upregulation of TRPV1 and Substance P receptors on nociceptors → Peripheral sensitization → reduced pain threshold
graph TD
A[Tissue Damage/Noxious Stimulus] --> B[TRPV1/TRPA1 Activation on C-fibres]
B --> C["Ca²⁺ Influx"]
C --> D[CGRP Vesicle Release]
D --> E[CGRP Binds CALCRL-RAMP1]
E --> F["Gs Protein → Adenylyl Cyclase"]
F --> G["cAMP ↑ → PKA Activation"]
G --> H[Vasodilation]
G --> I["Vascular Permeability ↑"]
G --> J[Mast Cell Activation]
J --> K["Histamine, TNF-α Release"]
K --> L[Amplified Inflammation]
D --> M[Sensitization of Nociceptors]
M --> N[Lower Pain Threshold]
N --> B
L --> B
Co-release with Substance P:
CGRP is typically co-released with Substance P from sensory nerve terminals, with synergistic effects:
- CGRP potentiates Substance P-induced plasma extravasation by 5-10 fold
- Substance P → NK1 receptor activation → amplifies CGRP release via positive feedback
- Combined release → neurogenic inflammation (the axon reflex-mediated inflammatory response)
Metabolic Inactivation:
CGRP is rapidly degraded by neutral endopeptidase (NEP) and cleared from circulation with t½ ~7 minutes, but tissue levels persist longer due to binding to receptors and extracellular matrix.
Migraine Pathophysiology:
CGRP levels increase 2-3 fold in jugular venous blood during Migraine attacks and normalize with successful treatment. The Trigeminovascular system—where trigeminal sensory neurons innervate cranial blood vessels and dura mater—is the primary anatomical substrate. During migraine, trigeminal activation releases CGRP around meningeal blood vessels, creating vasodilation, Mast Cell Degranulation, and sensitization that manifests as throbbing pain exacerbated by head movement or vascular pulsation.
Anti-CGRP Therapeutics:
- Monoclonal antibodies (erenumab, fremanezumab, galcanezumab): target CGRP or its receptor, reduce Migraine frequency by 50-60% in responders, administered monthly/quarterly
- Gepants (ubrogepant, rimegepant): small-molecule CGRP receptor antagonists, used for acute treatment and prevention, oral administration
- Therapeutic success confirms CGRP as a causal mediator, not just a correlate
Beyond Migraine:
CGRP elevation is implicated in:
cPNI Framework:
CGRP exemplifies the selfish nervous system—the peripheral nervous system prioritizes its own survival by creating local inflammatory responses independent of central control. This represents an evolutionary advantage (rapid local defense) that becomes a liability in chronic pain states where the system cannot down-regulate.
From a 5 plus 2 metamodel perspective:
- Metamodel 1 (Chronic stress): HPA-axis dysregulation fails to suppress CGRP-mediated inflammation
- Metamodel 2 (Low-grade inflammation): CGRP contributes to metaflammation by sensitizing immune cells
- Metamodel 3 (Insulin resistance): AGEs and hyperglycemia can trigger CGRP release via TRPA1 activation
Clinical Thresholds:
- Normal plasma CGRP: 2-5 pg/mL
- During migraine attack: 10-25 pg/mL
- Therapeutic anti-CGRP antibody target: reduce CGRP bioavailability by >50%
Intervention Implications:
Address CGRP upregulation via:
- 37-amino acid neuropeptide derived from alternative splicing of calcitonin gene (CALC1)
- One of the most potent vasodilators known—10-100× more potent than Substance P
- Plasma levels increase from baseline 2-5 pg/mL to 10-25 pg/mL during Migraine attacks
- Half-life in circulation ~7 minutes due to neutral endopeptidase degradation
- Receptor is heterodimeric complex: CALCRL + RAMP1 + RCP, coupled to Gs → cAMP → PKA
- Co-released with Substance P from C-fibres, producing synergistic inflammatory amplification (5-10× potentiation)
- Anti-CGRP monoclonal antibodies reduce migraine frequency by 50-60% in responders
- Gepants (small-molecule CGRP receptor antagonists) provide acute and preventive migraine treatment
- Implicated in dermatographia—visible skin wheal response from mechanical stimulation due to CGRP-mediated vasodilation and plasma leak
- Chronic elevation in Complex Regional Pain Syndrome contributes to osteopenia via osteoclast activation
- Activates Mast cells to release histamine, TNF-α, and prostaglandins, amplifying neurogenic inflammation
- Upregulates TRPV1 and Substance P receptors on sensory neurons, driving Peripheral sensitization
- Neurogenic inflammation — CGRP is the primary molecular mediator alongside Substance P
- Substance P — co-released neuropeptide that synergistically amplifies CGRP's inflammatory effects
- Migraine — elevated CGRP during attacks is both biomarker and causal mechanism
- Trigeminovascular system — anatomical location where trigeminal CGRP release causes migraine pain
- C-fibres — primary source of peripheral CGRP release in response to noxious stimuli
- TRPV1 — capsaicin receptor whose activation triggers CGRP release from sensory terminals
- TRPA1 — irritant receptor that also triggers CGRP release, activated by AGEs, oxidative stress
- Mast Cell Degranulation — CGRP directly activates mast cells to release inflammatory mediators
- Peripheral sensitization — CGRP lowers nociceptor threshold by upregulating pain receptors
- Central sensitization — chronic CGRP elevation contributes to spinal and suprathinal pain amplification
- Complex Regional Pain Syndrome — CGRP contributes to vasomotor changes, swelling, and bone loss
- Dermatographia — visible manifestation of CGRP-mediated vasodilation and plasma extravasation
- Fibromyalgia — elevated CGRP correlates with widespread pain and sensitization
- Chronic pain — persistent CGRP release maintains inflammatory and sensitization cascades
- Vasodilation — CGRP is 10-100× more potent than other vasodilators via cAMP-PKA pathway
- Tight junctions — CGRP disrupts endothelial tight junctions causing plasma leak
- Osteoclasts — CGRP directly activates bone-resorbing cells in chronic pain states
- Osteoblasts — CGRP inhibits bone-forming cells, contributing to net bone loss
- Magnesium — NMDA antagonism reduces trigeminal excitability and CGRP release
- Omega-3 fatty acids — compete with arachidonic acid pathways that amplify CGRP effects
- Specialized pro-resolving mediators (SPMs) — lipid mediators that can down-regulate CGRP-driven inflammation
- TNF-α — released by mast cells in response to CGRP, amplifying inflammation
- Histamine — co-released with CGRP from mast cells, contributing to vasodilation
- Calcitonin — alternative gene product from CALC1, illustrates evolutionary gene economy
- Module 5 (Neuroendocrinology)
- Module 11 (Pain & Inflammation)